Survival after surgery for spinal metastatic disease: a nationwide multiregistry cohort study

BMJ Open. 2021 Nov 1;11(11):e049198. doi: 10.1136/bmjopen-2021-049198.

Abstract

Objectives: To evaluate survival after surgery and indications for surgery due to spinal metastatic disease.

Design: A retrospective longitudinal multiregistry nationwide cohort study.

Setting: 19 public hospitals in Sweden with spine surgery service, where 6 university hospitals account for over 90% of the cases.

Participants: 1820 patients 18 years or older undergoing surgery due to spinal metastatic disease 2006-2018 and registered in Swespine, the Swedish national spine surgery registry.

Interventions: Decompressive and/or stabilising spine surgery due to spinal metastatic disease.

Primary outcome: Survival (median and mean) after surgery.

Secondary outcomes: Indications for surgery, types of surgery and causes of death.

Results: The median estimated survival after surgery was 6.2 months (95% CI: 5.6 to 6.8) and the mean estimated survival time was 12.2 months (95% CI: 11.4 to 13.1). Neurologic deficit was the most common indication for surgery and posterior stabilisation was performed in 70.5% of the cases. A neoplasm was stated as the main cause of death for 97% of the patients.

Conclusion: Both median and mean survival times were well above the generally accepted thresholds for surgical treatment for spinal metastases, suggesting that patient selection for surgical treatment on a national level is adequate. Further research on quality of life after surgery and prognostication is needed.

Keywords: neurosurgery; oncology; spine.

MeSH terms

  • Cohort Studies
  • Humans
  • Quality of Life*
  • Retrospective Studies
  • Spinal Neoplasms* / epidemiology
  • Spinal Neoplasms* / surgery
  • Survival Rate
  • Treatment Outcome